Clinical Trial Update: Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing bevacizumab with or without interferon alfa-2b in patients with metastatic melanoma has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Interferon alfa-2b (interferon alfa-2b)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2016-03-17